Loading…
Exagen Inc. is projected to rise to $7.06 by 2027, a +59% move from its current price of $4.45. XGN is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/12/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $4.26 | $4.46 | $4.66 | +0.12% |
| Jul 14 | $4.19 | $4.46 | $4.75 | +0.25% |
| Jul 15 | $4.14 | $4.47 | $4.82 | +0.37% |
| Jul 16 | $4.09 | $4.47 | $4.89 | +0.49% |
| Jul 17 | $4.05 | $4.48 | $4.94 | +0.61% |
| Jul 18 | $4.02 | $4.48 | $5.00 | +0.74% |
| Jul 19 | $3.99 | $4.49 | $5.05 | +0.86% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.99 | $4.49 | $5.05 | +0.86% |
| Week 2 | $3.83 | $4.53 | $5.34 | +1.73% |
| Week 3 | $3.73 | $4.57 | $5.59 | +2.61% |
| Week 4 | $3.64 | $4.61 | $5.82 | +3.49% |
| Week 5 | $3.57 | $4.64 | $6.04 | +4.38% |
| Week 6 | $3.51 | $4.68 | $6.24 | +5.28% |
| Week 7 | $3.46 | $4.73 | $6.44 | +6.19% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Exagen Inc. designs, develops, and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of complex rheumatic, and autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA).
Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases and other related diseases with overlapping symptoms. The company offers AVISE Lupus platform, a cornerstone of the SLE assessment that begins by quantifying the level of CB-CAPs biomarkers (EC4d and BC4d) in the patients blood; and AVISE APS that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE Anti-Histone, a test for autoantibodies to histone proteins; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP, a biomarker-driven RA prognostic test.
Further, the company offers AVISE SLE Monitor, a blood test that employs CB-CAPs technology; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.
It has a research collaboration and license agreement with Allegheny Health Network AHN Research Institute to develop T-Cell biomarkers. The company was formerly known as Exagen Diagnostics, Inc. and changed its name to Exagen Inc. in January 2019. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.
Exagen Inc. (XGN) operates in the healthcare sector as a provider of autoimmune testing products under the AVISE brand. The stock is currently trading at $4.64 per share and has a market capitalization of $112.1M, with a rank of 4148.
The forecast highlights a long-term upside pathway, starting from a 2026 average around the current level and expanding meaningfully into the 2030s and 2040s, culminating in multi-decade levels in the 2050s. The 2026 forecast shows an average of $4.64, with higher averages and sizeable gains evident in subsequent years (e.g., 2027 avg $7.85, 2028 avg $9.36, 2029 avg $10.49, 2030 avg $10.51, 2040 avg $41.20, and 2050 avg $76.62). These figures accompany rising sentiment and progressively larger ROIs across the timeline.
A major floor 40.4% below — a decisive break under it would weaken the trend.
The nearest floor, 5.8% below — buyers have tended to step in here.
The nearest ceiling, 20.2% above — a clean break opens room to run.
A major ceiling 30.9% above — clearing it would confirm fresh momentum.
Key XGN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of XGN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.53 | Sell | $4.53 | Sell |
| MA 10 | $4.59 | Sell | $4.54 | Sell |
| MA 20 | $4.54 | Sell | $4.51 | Sell |
| MA 50 | $4.18 | Buy | $4.25 | Buy |
| MA 100 | $3.65 | Buy | $4.32 | Buy |
| MA 200 | $5.74 | Sell | $4.93 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 49.94 | Neutral |
| Stoch RSI (14) | 15.37 | Buy |
| CCI (20) | -55.58 | Neutral |
| Williams %R (14) | -78.65 | Info |
| MACD (12,26,9) | -0.04 | Sell |
| ROC (12) | 2.18 | Buy |
| Bollinger %B (20,2) | 0.33 | Neutral |
| Stochastic %K (14) | 21.35 | Neutral |
| TRIX (15) | 0.39 | Buy |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 45.34 | Neutral |
| Momentum (10) | -0.19 | Sell |
| Aroon Osc (25) | 68.00 | Buy |
| Hull MA (9) | 4.50 | Sell |
| ADX (14) | 11.33 | Neutral |
| ATR (14) | 0.20 | Info |
The near-term picture is bullish, with the sentiment labeled as bullish in the 30-day window and an RSI of 60. The stock trades around key moving averages, with the SMA50 at $3.84 and the SMA200 at $5.99.
Support is identified at $3.47 and resistance at $5.35, framing a 30-day trading range from $3.47 to $6.20. Annualized volatility is elevated at 80%, indicating notable price movement potential within the month.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.65 | $4.45 | $7.28 | 0% | Neutral | |
| $5.30 | $7.06 | $10.13 | +59% | Bullish | |
| $6.25 | $8.75 | $13.26 | +97% | Bullish | |
| $6.56 | $9.56 | $15.11 | +115% | Bullish | |
| $6.09 | $9.21 | $15.09 | +107% | Bullish | |
| $6.73 | $10.53 | $17.79 | +137% | Bullish | |
| $7.64 | $12.35 | $21.42 | +177% | Bullish | |
| $9.97 | $16.63 | $29.56 | +274% | Bullish | |
| $11.66 | $20.03 | $36.41 | +350% | Bullish | |
| $10.06 | $17.78 | $32.98 | +300% | Bullish | |
| $16.72 | $33.85 | $68.37 | +661% | Bullish | |
| $26.92 | $59.82 | $136.25 | +12.4x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $2.65 | $4.45 | $5.73 | +0.00% |
| August 2026 | $4.04 | $4.85 | $6.04 | +9.05% |
| September 2026 | $4.10 | $4.98 | $6.30 | +2.54% |
| October 2026 | $4.44 | $5.44 | $6.99 | +9.36% |
| November 2026 | $4.60 | $5.69 | $7.40 | +4.60% |
| December 2026 | $4.44 | $5.54 | $7.28 | -2.75% |
Click any year to see its month-by-month XGN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, XGN could reach as high as $7.28, with a base case around $4.45 and support toward $2.65 — roughly 0% from $4.45. Price action looks broadly range-bound.
Expect XGN to range from $5.30 to $10.13 through 2027. The $7.06 average target implies a +59% move from current prices. That is up +59% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The XGN price prediction for 2028 points to an average of $8.75 (low $6.25, high $13.26) — a potential gain of +97% on today's $4.45. Momentum favours further upside here.
In 2029, XGN is projected to trade between $6.56 and $15.11, averaging $9.56 — a potential gain of +115% from today's $4.45. That is up +9% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Exagen Inc.'s 2030 outlook centres on $9.21, within a $6.09 to $15.09 range. That is -4% versus the projected 2029 average. That marks a +107% change versus current levels. Momentum favours further upside here.
By 2031, XGN could reach as high as $17.79, with a base case around $10.53 and support toward $6.73 — roughly +137% from $4.45. Buyers look set to stay in control over this stretch.
Expect XGN to range from $7.64 to $21.42 through 2032. The $12.35 average target implies a +177% move from current prices. That is up +17% on the projected 2031 average. Momentum favours further upside here.
The XGN price prediction for 2033 points to an average of $16.63 (low $9.97, high $29.56) — a potential gain of +274% on today's $4.45. Buyers look set to stay in control over this stretch.
In 2034, XGN is projected to trade between $11.66 and $36.41, averaging $20.03 — a potential gain of +350% from today's $4.45. That is up +20% on the projected 2033 average. Momentum favours further upside here.
Exagen Inc.'s 2035 outlook centres on $17.78, within a $10.06 to $32.98 range. That is -11% versus the projected 2034 average. That marks a +300% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, XGN could reach as high as $68.37, with a base case around $33.85 and support toward $16.72 — roughly +661% from $4.45. Momentum favours further upside here.
Expect XGN to range from $26.92 to $136.25 through 2050. The $59.82 average target implies a +12.4x move from current prices. That is up +77% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in XGN today (≈ 224.719101 XGN) could be worth
$13,442.42
+$12,442.42 (+1244%) by 2050 · US Dollar
Based on the average projected XGN price of $59.82 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in XGNwould be worth at today's price.
$1,000 invested in XGN on Jul 10, 2025 (≈ 142.857143 XGN) would be worth
$635.71
-$364.29 (-36.4%) today · 0.64× · US Dollar
Based on a XGN entry price of $7 vs. today's $4.45.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.54 | $980.18 | -2.0% |
| 1 month ago | $4.19 | $1,062.05 | +6.2% |
| 3 months ago | $3.03 | $1,468.65 | +46.9% |
| 6 months ago | $5.95 | $747.9 | -25.2% |
| 1 year ago | $7 | $635.71 | -36.4% |
| All time (5.0y) ago | $13.92 | $319.68 | -68.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our XGN forecast.
Our base-case forecast reaches $8.90 around 2029.
Implied market cap at $8.90: $215.02M
The multi-year outlook shows a clear upward trajectory. The 2027 forecast average is $7.85 with a 69.2% ROI and a bullish sentiment, followed by 2028 at $9.36 (101.8%), 2029 at $10.49 (126.2%), and 2030 at $10.51 (126.5%), all with bullish sentiment.
Beyond 2030, the forecast envisions substantial upside, with 2040 averaging $41.20 and a 787.9% ROI, and 2050 averaging $76.62 with a 1551.3% ROI, both labeled bullish. These are estimates and not guarantees; they reflect modeled expectations over a long horizon and are subject to change with market conditions and company performance.
Tap a question to reveal the answer.
The 2030 forecast shows an average price of $10.51 with a minimum of $6.95 and a maximum of $17.20, and a predicted ROI of 126.5% with bullish sentiment.
Longer-term forecasts show bullish sentiment from 2027 onward, with rising averages and high potential ROIs, including 2040 at $41.20 (787.9% ROI) and 2050 at $76.62 (1551.3% ROI). These are estimates, not guarantees.
Yes. The forecast includes years where the maximum price exceeds $15 (2032 max $25.60; 2033 max $35.52; 2034 max $41.56), and the 2033 average is $20.00, indicating the potential to surpass $15 in the forecast window.
$112.1M.
Exagen Inc. Community Discussion
0Share your Exagen Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.